ap26113 resistance in lymphoma

Several NPM-ALK resistant mutatations were identified in the lab. They provide targets for future research.

http://www.ncbi.nlm.nih.gov/pubmed/25421750

This entry was posted in Anaplastic Large-Cell Lymphomas, AP26113 - brigatinib from Ariad, Research, Resistance to treatment. Bookmark the permalink.

Leave a Reply